Thera-SAbDab

LACNOTUZUMAB

>   Structural Summary
TherapeuticLacnotuzumab
TargetCSF1
Heavy ChainQVQLQESGPGLVKPSQTLSLTCTVSDYSITSDYAWNWIRQFPGKGLEWMGYISYSGSTSYNPSLKSRITISRDTSKNQFSLQLNSVTAADTAVYYCASFDYAHAMDYWGQGTTVTVSS
Light ChainDIVLTQSPAFLSVTPGEKVTFTCQASQSIGTSIHWYQQKTDQAPKLLIKYASESISGIPSRFSGSGSGTDFTLTISSVEAEDAADYYCQQINSWPTTFGGGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2016
INN Year Recommended2017
Companies InvolvedDana-Farber Cancer Institute, Novartis, Novartis Oncology, Seoul National University Hospital
Conditions Approvedna
Conditions ActiveBreast cancer, Gastric cancer, Giant cell tumour of tendon sheath, Pigmented villonodular synovitis, Malignant melanoma, Solid tumours
Conditions DiscontinuedBone metastases, Prostate cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]